Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

BACKGROUND: Anagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however remains uncertain. AIM AND METHODS: We therefore evaluate the effects of anaglipt...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Chihara, Atsuko, Tanaka, Atsushi, Morimoto, Takeshi, Sakuma, Mio, Shimabukuro, Michio, Nomiyama, Takashi, Arasaki, Osamu, Ueda, Shinichiro, Node, Koichi
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858725/
https://ncbi.nlm.nih.gov/pubmed/31733647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0965-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados